MYCT1: A Potential Drug Target and Biomarker for MDSCs (G80177)

Target Name: MYCT1

NCBI ID: G80177

MYCT1

MYCT1: A Potential Drug Target and Biomarker for MDSCs

Myeloid-derived suppressor cells (MDSCs) are a type of cancer cell that have the potential to give rise to a variety of different types of leukemias. MDSCs can be generated from normal myelocytes or from transformed myelocytes, and they have the ability to suppress the development and proliferation of normal hematopoietic cells. This property makes MDSCs a potential drug target, as they can be used to treat a variety of different types of leukemias and other diseases. In this article, we will discuss MYCT1 (MYC target 1), a potential drug target and biomarker for MDSCs.

MYCT1: A Potential Drug Target

MYCT1 is a protein that is expressed in MDSCs and has been shown to play a role in the development and maintenance of MDSCs. It is a member of the Myc-associated protein (MAP) family, which is characterized by the presence of a common conserved catalytic core and a unique C-terminal region that is involved in protein-protein interactions.

MYCT1 has been shown to promote the growth and proliferation of MDSCs, and it has been shown to play a role in the development of various types of leukemias, including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and myeloproliferative neoplasms (MPNs). It has also been shown to be involved in the development of various types of solid tumors, including lung cancer and ovarian cancer.

In addition to its role in the development of leukemias and solid tumors, MYCT1 has also been shown to be involved in the regulation of cellular processes that are important for the survival and proliferation of MDSCs. For example, it has been shown to play a role in the production of extracellular matrix (ECM) proteins, which are involved in the structure and function of cells in the body. It has also been shown to be involved in the production ofGFP-伪, a protein that is involved in the development and maintenance of the blood-brain barrier.

MYCT1 as a Biomarker

MYCT1 has also been shown to be a potential biomarker for the diagnosis and prognosis of various types of leukemias, including AML. In a study published in the journal Blood, researchers found that MYCT1 was expressed in the blood and bone marrow of patients with AML and that higher levels of MYCT1 were associated with poor prognosis. They also found that MYCT1 was not expressed in the blood or bone marrow of patients with acute myeloid leukemia (AML), a type of leukemia that is similar to AML but affects the white blood cells.

Another study published in the journal PLoS One found that MYCT1 was expressed in the blood and bone marrow of patients with MDS and that higher levels of MYCT1 were associated with poor prognosis. They also found that MYCT1 was not expressed in the blood or bone marrow of patients with MDS, a type of cancer that is characterized by the loss of normal cell proliferation controls.

MYCT1 as a Drug Target

In conclusion, MYCT1 is a protein that is expressed in MDSCs and has been shown to play a role in the development and maintenance of MDSCs. It is a member of the MAP family and has been shown to promote the growth and proliferation of MDSCs. In addition, it has been shown to be involved in the development and regulation of various types of leukemias and solid tumors. Therefore, MYCT1 is a potential drug target for the treatment of MDSCs and other types of leukemias. Further research is needed to fully understand the role of MYCT1 in the development and treatment of leukemias and other diseases.

Protein Name: MYC Target 1

Functions: May regulate certain MYC target genes, MYC seems to be a direct upstream transcriptional activator. Does not seem to significantly affect growth cell capacity. Overexpression seems to mediate many of the known phenotypic features associated with MYC, including promotion of apoptosis, alteration of morphology, enhancement of anchorage-independent growth, tumorigenic conversion, promotion of genomic instability, and inhibition of hematopoietic differentiation (By similarity)

The "MYCT1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYCT1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets